NO20074514L - Oral doseringsform omfattende rosiglitazon - Google Patents
Oral doseringsform omfattende rosiglitazonInfo
- Publication number
- NO20074514L NO20074514L NO20074514A NO20074514A NO20074514L NO 20074514 L NO20074514 L NO 20074514L NO 20074514 A NO20074514 A NO 20074514A NO 20074514 A NO20074514 A NO 20074514A NO 20074514 L NO20074514 L NO 20074514L
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- composition
- oral dosage
- rosiglitazone
- pellets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0502479.9A GB0502479D0 (en) | 2005-02-07 | 2005-02-07 | Novel compositions |
PCT/EP2006/000999 WO2006082089A1 (en) | 2005-02-07 | 2006-02-03 | Oral dosage form comprising rosiglitazone |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20074514L true NO20074514L (no) | 2007-09-05 |
Family
ID=34355902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074514A NO20074514L (no) | 2005-02-07 | 2007-09-05 | Oral doseringsform omfattende rosiglitazon |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080139624A1 (pt) |
EP (1) | EP1845977A1 (pt) |
JP (1) | JP2008529984A (pt) |
KR (1) | KR20070104392A (pt) |
CN (1) | CN101155585A (pt) |
AU (1) | AU2006210135A1 (pt) |
BR (1) | BRPI0606768A2 (pt) |
CA (1) | CA2595409A1 (pt) |
EA (1) | EA200701680A1 (pt) |
GB (1) | GB0502479D0 (pt) |
IL (1) | IL184787A0 (pt) |
MA (1) | MA29280B1 (pt) |
MX (1) | MX2007009493A (pt) |
NO (1) | NO20074514L (pt) |
TW (1) | TW200640455A (pt) |
WO (1) | WO2006082089A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
EP2476418A1 (en) * | 2006-12-21 | 2012-07-18 | Alphapharm Pty Ltd. | Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size |
GEP20135845B (en) | 2008-03-11 | 2013-06-10 | Takeda Pharmaceutical | Orally-disintegrating solid formulation |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068278A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-associations |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
CN109481419B (zh) * | 2019-01-16 | 2021-04-02 | 中国人民解放军陆军军医大学第一附属医院 | 一种罗格列酮纳米制剂及其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
WO2004112756A1 (en) * | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
TW200517127A (en) * | 2003-08-07 | 2005-06-01 | Sb Pharmco Inc | Novel composition |
WO2005065654A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Rosiglitazone formulations |
-
2005
- 2005-02-07 GB GBGB0502479.9A patent/GB0502479D0/en not_active Ceased
-
2006
- 2006-02-03 JP JP2007553551A patent/JP2008529984A/ja not_active Withdrawn
- 2006-02-03 CA CA002595409A patent/CA2595409A1/en not_active Abandoned
- 2006-02-03 WO PCT/EP2006/000999 patent/WO2006082089A1/en active Application Filing
- 2006-02-03 KR KR1020077018030A patent/KR20070104392A/ko not_active Application Discontinuation
- 2006-02-03 US US11/815,333 patent/US20080139624A1/en not_active Abandoned
- 2006-02-03 AU AU2006210135A patent/AU2006210135A1/en not_active Abandoned
- 2006-02-03 BR BRPI0606768-9A patent/BRPI0606768A2/pt not_active IP Right Cessation
- 2006-02-03 CN CNA2006800111169A patent/CN101155585A/zh active Pending
- 2006-02-03 EP EP06701697A patent/EP1845977A1/en not_active Withdrawn
- 2006-02-03 EA EA200701680A patent/EA200701680A1/ru unknown
- 2006-02-03 MX MX2007009493A patent/MX2007009493A/es not_active Application Discontinuation
- 2006-02-06 TW TW095103943A patent/TW200640455A/zh unknown
-
2007
- 2007-07-23 IL IL184787A patent/IL184787A0/en unknown
- 2007-08-31 MA MA30181A patent/MA29280B1/fr unknown
- 2007-09-05 NO NO20074514A patent/NO20074514L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0606768A2 (pt) | 2009-07-14 |
EP1845977A1 (en) | 2007-10-24 |
JP2008529984A (ja) | 2008-08-07 |
MA29280B1 (fr) | 2008-02-01 |
AU2006210135A1 (en) | 2006-08-10 |
MX2007009493A (es) | 2007-09-19 |
TW200640455A (en) | 2006-12-01 |
CN101155585A (zh) | 2008-04-02 |
IL184787A0 (en) | 2007-12-03 |
GB0502479D0 (en) | 2005-03-16 |
EA200701680A1 (ru) | 2007-12-28 |
KR20070104392A (ko) | 2007-10-25 |
WO2006082089A1 (en) | 2006-08-10 |
CA2595409A1 (en) | 2006-08-10 |
US20080139624A1 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074514L (no) | Oral doseringsform omfattende rosiglitazon | |
NO20074407L (no) | Oral doseringsform omfattende rosiglitazon | |
AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
YU16303A (sh) | Tartaratne soli derivata tiazolidindiona | |
AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika | |
NO20076517L (no) | Natriumsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksyl]benzyl]tiazolidin-2,4-dion | |
AP1785A (en) | Tartrate salt of thiazolidinedione derivative. | |
AP2003002737A0 (en) | Tartrate salts of thiazolidinedione derivatives | |
MXPA02012100A (es) | Sal de tiazodilindiona para el tratamiento de la diabetes mellitus. | |
CY1107421T1 (el) | Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης | |
DK1315724T3 (da) | Thiazolidindionderivat og dets anvendelse som antidiabetikum | |
WO2003099337A3 (en) | Inclusion complexes of rosiglitazone | |
HRP20010344B1 (en) | Novel method of treatment | |
AP1841A (en) | A thiazolidinedione derivative and its use as antidiabetic. | |
Tablets | PROTONIX® | |
TH84984B (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน | |
CY1106397T1 (el) | Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο | |
Udupa | Proton Pump Inhibitors–An Overview | |
BRPI0607804A2 (pt) | braçadeira de lámina despeladora com ranhuras de saìda de gordura | |
TH85149B (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน | |
TH84984A (th) | รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |